Bisphosphonate efficacy and clinical trials for postmenopausal osteoporosis: Similarities and differences

Bone

Volumn 40, Issue 5 SUPPL. 2, 2007, Pages

  Boonen, Steven ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Alendronate; Bisphosphonates; Hip fracture; Ibandronate; Nonvertebral fracture; Osteoporosis; Risedronate; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; HIP FRACTURE; HUMAN; MULTIPLE CYCLE TREATMENT; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; VERTEBRA FRACTURE;

EID: 34147123172     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.03.003     Document Type: Article

References (21)

1. World Health Organization. Osteoporosis: both health organizations and individuals must act now to avoid an impending epidemic. Press release WHO/58 11 October 1999. Available at: www.who.int/inf-pr-1999/en/pr99-58.html. Accessed March 4, 2006.
2. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
3. Chesnut III C., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19 (2004) 1241-1249
4. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos. Int. 11 (2000) 83-91
5. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296 (2001) 235-242
6. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
7. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C., et al. Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin. Endocrinol. Metab. 85 (2000) 4118-4124
8. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
9. Watts N.B., Adami S., and Chesnut C.H. Risedronate reduces the risk of clinical vertebral fractures in just 6 months. J. Bone Miner. Res. 16 Suppl. 1 (2001) 262 [Abstract SU409]
10. Boonen S., Laan R.F., Barton I.P., and Watts N.B. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos. Int. 16 (2005) 1291-1298
11. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344 (2001) 333-340
12. Papapoulos S.E., Quandt S.A., Liberman U.A., Hochberg M.C., and Thompson D.E. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos. Int. 16 (2005) 468-474
13. Bone H.G., Hosking D., Devogelaer J.P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350 (2004) 1189-1199
14. Mellstrom D.D., Sorensen O.H., Goemaere S., Roux C., Johnson T.D., and Chines A.A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif. Tissue Int. 75 (2004) 462-468
15. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., et al. Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20 (2005) 141-151
16. Hochberg M.C., Ross P.D., Black D., Cummings S.R., Genant H.K., Nevitt M.C., et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 42 (1999) 1246-1254
17. Watts N.B., Cooper C., Lindsay R., Eastell R., Manhart M.D., Barton I.P., et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J. Clin. Densitom. 7 (2004) 255-261
18. Watts N.B., Geusens P., Barton I.P., and Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J. Bone Miner. Res. 20 (2005) 2097-2104
19. Hosking D., Adami S., Felsenberg D., Andia J.C., Välimäki M., Benhamou L., et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr. Med. Res. Opin. 19 (2003) 383-394
20. Greenwald M., Fischer M., Poiley J., Bos K., and Reginster J. Rapid and consistent effect of risedronate on vertebral fracture risk reduction in elderly postmenopausal women. J. Bone Miner. Res. 15 Suppl. 1 (2000) S226 [Abstract F386]
21. Dufresne T.E., Chmielewski P.A., Manhart M.D., Johnson T.D., and Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif. Tissue Int. 73 (2003) 423-432